Personalised Risk-directed Clot Prevention For Patients With Cancer
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Blood clots are a leading cause of death among cancer patients, second only to cancer itself. This EL1 program includes clinical and laboratory studies to assess the impact of personalised clot prevention for patients receiving cancer treatments in ambulatory care settings. Laboratory studies and evaluation of outcomes among ‘real-world’ patients with cancers at high risk of developing blood clots, will improve understanding of both clots and cancer, to advance research and clinical practice.
Early Life Exposures And Chronic Disease: Mechanisms And Preventative Strategies
Funder
National Health and Medical Research Council
Funding Amount
$2,714,215.00
Summary
The world is in the grips of an epidemic of chronic disease and exposure to pollution in early life is partly responsible. To change this situation we need to understand and mitigate the mechanisms linking early life pollution exposure to life-long disease risk. My research will provide direct evidence of how pollution increases disease risk and design and implement strategies to reduce this, with an emphasis on asthma, cystic fibrosis and chronic respiratory disease.
Reducing The Burden Of Breast Cancer Through Precision Prevention, Targeted Treatment And Enhanced Survivorship
Funder
National Health and Medical Research Council
Funding Amount
$1,491,192.00
Summary
Breast cancer affects 1 in 8 Australian women. Of all the cancers, breast cancer results in the largest number of years of healthy life lost from death and illness. My research will reduce this unacceptable burden of breast cancer for women and their families. Spanning prevention, through treatment to survivorship, it will facilitate reduced breast cancer incidence, more effective treatments and enhanced understanding of the effects of new treatments on ovarian function and fertility.